Fig. 1 · Structure

Documents & Downloads

NSC 405020

Cat. No. A13072 CAS 7497-07-6

MT1-MMP inhibitor

NSC-405020 is a membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC50 > 100 μmol/L).

In Stock

Publications for NSC 405020

1 publication citing this product

  1. Kittaka M, .et al. , J Bone Miner Res, 2018, Jan;33(1):167-181 PMID: 28914985

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

NSC 405020 is used to investigate noncatalytic MT1-MMP/MMP14 function. In the original study, compound 9 had a catalytic-domain IC50 >100 µM and reduced MT1-MMP association in a cellular pull-down assay at 100 µM. These findings support a noncatalytic mechanism consistent with interference in PEX-dependent homodimerization; they do not establish a binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MT1-MMP

NSC 405020 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of NSC 405020 from 3 published references. In vitro models include purified MT1-MMP catalytic domain (CAT), fluorescent peptide cleavage.

NSC 405020 In Vitro Studies

In WM852 melanoma–lymphatic endothelial co-cultures, 50 µM NSC 405020 for 48 h reduced the actin-normalized combined Notch3/NICD3 immunoblot signal relative to DMSO-treated co-cultures. This result supports a cellular pathway response in that model. [2]

Isolated MT1-MMP catalytic-domain assay

Biochemical assay · Purified MT1-MMP catalytic domain (CAT), fluorescent peptide cleavage [1]

The reported IC50 exceeds 100 µM for catalytic-domain inhibition; this is a lower bound in a catalytic assay, not potency for PEX-dependent cellular effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of fluorescent peptide cleavage by MT1-MMP CATIC50 >100 µM[1]

Literature-Reported Treatment Conditions

Method
Concentration-dependent fluorescent peptide cleavage assay
Reported limits
The complete concentration series and matched vehicle details are not specified in the selected assay description; the figure reports the IC50 bound.
Methods and source locations

Compound reported in the paper: NSC 405020; Compound label in the paper: Compound 9 (NSC405020)

Evidence concerns the reported NSC405020 material; it does not establish stereoisomer-specific activity or validate a current Adooq lot.

Figure 4, compound 9; Methods: Cleavage of fluorescent peptide; Compound databases

Inhibition of fluorescent peptide cleavage by MT1-MMP CAT: 10 nM CAT and 10 µM fluorescent peptide substrate; 30 min compound preincubation at ambient temperature, activity measured at 37°C; triplicate assay. — Figure 4, compound 9; Methods: Cleavage of fluorescent peptide

Cellular MT1-MMP homodimerization

Cell-based study · MCF7-MT-V5 cells expressing MT1-MMP-FLAG; untagged MCF7-MT cells as control [1]

NSC405020 reduced co-precipitated MT1-MMP-V5 in the FLAG pull-down assay, consistent with interference in MT1-MMP homodimerization.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MT1-MMP-V5 recovered in anti-FLAG precipitatesQualitative immunoblot result Reduced with compound 9; compound 14 did not show this effect[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 µM
Exposure duration
24 h compound exposure, beginning 24 h after transfection
Method
Cell treatment followed by co-immunoprecipitation and western blot
Vehicle
DMSO; concentration not specified for this experiment
Reported limits
No numerical dimerization effect size, binding constant or replicate count is stated for this blot.
Methods and source locations

Compound reported in the paper: NSC 405020; Compound label in the paper: Compound 9 (NSC405020)

Evidence concerns the reported NSC405020 material; it does not establish stereoisomer-specific activity or validate a current Adooq lot.

Figure 5F; Results: Compound 9 affects the PEX function; Methods: Cells and Compound databases

MT1-MMP-V5 recovered in anti-FLAG precipitates: Anti-FLAG pull-down followed by anti-V5 western blot; DMSO comparison, untagged MT1-MMP control and actin loading control. — Figure 5F and caption; Results: Compound 9 affects the PEX function

Notch3 response in melanoma–lymphatic endothelial co-culture

Cell-based study · Human WM852 melanoma cells co-cultured with primary lymphatic endothelial cells (LECs), followed by magnetic separation [2]

NSC405020 decreased the actin-normalized combined full-length Notch3 and NICD3 band signal in LEC-co-cultured WM852 cells compared with the DMSO co-culture control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Combined Notch3 and cleaved NICD3 band intensity normalized to actinDirection of change Decreased versus DMSO-treated WM852–LEC co-culture[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 µM
Exposure duration
48 h during 2D LEC–WM852 co-culture
Method
Addition to growth medium during co-culture, then separation and immunoblot
Vehicle
DMSO comparator shown; final concentration not specified
Reported limits
Final DMSO concentration is not specified. Exact percentage effects are withheld; see private review.
Methods and source locations

Compound reported in the paper: NSC 405020; Compound label in the paper: NSC405020

Compound-level applicability; no claim that an Adooq lot was tested in this study.

Results: MMP14 is required for the invasively sprouting 3D growth of LEC primed melanoma cells (NSC405020 paragraph); Figure 4—figure supplement 2d–e; Key resources; Methods: Inhibitor treatments, Western blot, Statistical analysis

Combined Notch3 and cleaved NICD3 band intensity normalized to actin: Western blot and Image Lab densitometry; two independent experiments, mean ± SD in supplement panel e; untreated and DMSO ±LEC comparison lanes in panel d. — Figure 4—figure supplement 2d–e and caption; Methods: Western blot; Statistical analysis

NSC 405020 In Vivo Studies

In c-Fos-deficient Sh3bp2KI/KI cherubism mice, subcutaneous NSC405020 at 50 mg/kg/day from 4 to 10 weeks of age reduced distal tibial bone erosion relative to vehicle. The result is confined to this specialized mouse model. [3]

Bone erosion in c-Fos-deficient cherubism mice

Animal study · c-Fos−/− Sh3bp2KI/KI mice; distal tibia [3]

NSC405020 treatment reduced eroded bone surface area relative to vehicle in this specialized inflammatory bone-destruction model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Distal tibial eroded bone surface areaDirection of change Reduced versus vehicle[3]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Daily (reported as mg/kg/day)
Treatment course
From 4 to 10 weeks of age
Vehicle
Vehicle comparator in Figure 5H/I; composition not specified in the inhibitor-treatment section or caption
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NSC405020 versus vehicle
50 mg/kg/day
Vehicle-treated c-Fos-deficient Sh3bp2KI/KI miceReduced distal tibial eroded bone surface area[3]
NSC405020 versus vehicle
Model: c-Fos−/− Sh3bp2KI/KI mice
Reported limits: Exact group n is not stated in the Figure 5H/I caption or selected treatment text; no numerical mean or SD is transcribed from the graph. Treatment-group sex allocation and vehicle composition are not specified.
Methods and source locations

Compound reported in the paper: NSC 405020; Compound label in the paper: NSC405020

Historical use of AdooQ-supplied NSC405020 in the reported mouse model; not a current-lot quality validation.

Figure 5H–I; Results: Macrophages expressing MMP14 are responsible for bone erosion; Methods: MMP14 inhibitor treatment, Quantification of bone erosion

Distal tibial eroded bone surface area: Ex-vivo microCT reconstruction; distal 1 mm tibial region; ImageJ measurements of four periosteal views averaged per mouse, performed blinded. Figure 5 presents mean ± SD; no exact graph values inferred. — Figure 5H–I and caption; Methods: Ex-vivo microCT imaging; Quantification of bone erosion

NSC405020 versus vehicle · Figure 5H–I; Methods: MMP14 inhibitor treatment; Quantification of bone erosion

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 7497-07-6
Applications MT1-MMP inhibitor
Formula C12H15Cl2NO
Molecular Weight 260.16
SMILES
CCCC(C)NC(=O)C1=CC(=C(C=C1)Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 48 mg/mL (184.5 mM)
Water Insoluble
Ethanol 48 mg/mL (184.5 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NSC 405020 Research References

  1. [1] Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth Cancer research (2012). PMID: 22406620 DOI: 10.1158/0008-5472.can-11-4149 Source material
  2. [2] Pekkonen P, Alve S, Balistreri G, et al. Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation eLife (2018). PMID: 29712618 DOI: 10.7554/elife.32490 Source material
  3. [3] Kittaka M, Mayahara K, Mukai T, et al. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2018). PMID: 28914985 DOI: 10.1002/jbmr.3295 Source material

Publications

1 publication citing this product

  1. Kittaka M, .et al. , J Bone Miner Res, 2018, Jan;33(1):167-181 PMID: 28914985

Added to your cart

View Cart Checkout
Loading...